12
Jul
Jul
On July 9, 2024, the U.S. FDA authorized ZORYVE from Arcutis Biotherapeutics® (roflumilast) for the therapy of atopic dermatitis (AD), probably the most frequent sort of eczema affecting hundreds of thousands of individuals in the US. This once-daily, steroid-free cream may develop into a fresh normal of take care of AD. The approval highlights the […]